Daratumumab‐Based Combinational Therapy as Second‐Line Treatment of Relapsed‐Refractory Multiple Myeloma: A Single‐Center Experience
In our single-center experience with Taiwanese RRMM patients, daratumumab in combinational therapy showed promising efficacy, and modest tolerance in the second-line setting.
Authors
- Ken‐Hong Lim (ORCID: https://orcid.org/0000-0003-2282-0416)
- Caleb Gon‐Shen Chen
- Oscar C. Y. Yang (ORCID: https://orcid.org/0000-0001-7207-8868)
- Yi‐Hao Chiang (ORCID: https://orcid.org/0009-0005-8170-8629)
- Huan‐Chau Lin (ORCID: https://orcid.org/0000-0003-3382-9176)
- Johnson Lin (ORCID: https://orcid.org/0000-0002-9621-9343)
- Yu‐Cheng Chang (ORCID: https://orcid.org/0009-0000-1760-2719)
- Ming‐Chih Chang
Institutions
- Mackay Memorial Hospital (TW)
- Mackay Medical University (TW)
Publication Details
- Journal
- Cancer Reports
- Published
- 2025-11-29
- DOI
- https://doi.org/10.1002/cnr2.70367
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00